• Explore /
  • Poster
  • / Utilization and patient characteristics for the trastuzumab originator, biosimilars, and other HER2 inhibitors in the United States.

Utilization and patient characteristics for the trastuzumab originator, biosimilars, and other HER2 inhibitors in the United States.

Abstract Poster

Authors

null

Young Hee Nam

Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA

Young Hee Nam, Aaron Mendelsohn, James Marshall, Nancy Lin, Jeffrey Brown, Cara McDermott, Pamala A. Pawloski, Catherine Lockhart

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session B: Patient Experience; Quality, Safety, and Implementation Science; Technology and Innovation in Quality of Care

Track

Technology and Innovation in Quality of Care,Patient Experience,Quality, Safety, and Implementation Science,Cost, Value, and Policy,Health Care Access, Equity, and Disparities

Sub Track

Real-World Evidence

Citation

J Clin Oncol 39, 2021 (suppl 28; abstr 308)

DOI

10.1200/JCO.2020.39.28_suppl.308

Abstract #

308

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Anna-Maria Lazaratos

First Author: Audrey Mailliez

First Author: Julien Mazières

First Author: Erika Paige Hamilton